Literature DB >> 31819632

Perfusion, Diffusion, Or Brain Tumor Barrier Integrity: Which Represents The Glioma Features Best?

Lin-Feng Yan1, Ying-Zhi Sun1, Sha-Sha Zhao1, Yu-Chuan Hu1, Yu Han1, Gang Li2, Xin Zhang1, Qiang Tian1, Zhi-Cheng Liu1, Yang Yang1, Hai-Yan Nan1, Ying Yu1, Qian Sun1, Jin Zhang1, Ping Chen1, Bo Hu1, Fei Li3, Teng-Hui Han3, Wen Wang1, Guang-Bin Cui1.   

Abstract

PURPOSE: This study aims to incorporate informative histogram indicator analyses and advanced multimodal MRI parameters to differentiate low-grade gliomas (LGGs) from high-grade gliomas (HGGs) and to explore the features associated with patients' survival. PATIENTS AND METHODS: A total of 120 patients with pathologically confirmed LGGs or HGGs receiving conventional and advanced MRI such as three-dimensional arterial spin labeling (3D-ASL), intravoxel incoherent motion-diffusion weighted imaging (IVIM-DWI), and dynamic contrast-enhanced MRI (DCE-MRI) were included. The mean and histogram indicators from advanced MRI were calculated from the entire tumor. The efficacies of a single indicator or multiple parameters were tested in distinguishing HGGs from LGGs and predicting patients' survival. Receiver operating characteristic (ROC) curve and multivariable stepwise logistic regression were used to evaluate the diagnostic efficacies. Leave-one-out cross-validation was further used to validate the accuracy of the parameter sets in glioma grading. Log-rank test using the Kaplan-Meier curve was utilized to predict patients' survival.
RESULTS: Overall, parameters from DCE-MRI performed better than those from 3D-ASL or IVIM-DWI in both glioma grading and survival prediction. The histogram metrics of Ve were demonstrated to have higher accuracies (the accuracies for Extended Tofts_Ve mean and Extended Tofts_Ve median were 68.33% and 71.67%, respectively, while those for the Incremental_Ve mean and Incremental_Ve 75th were 68.33% and 72.50%, respectively) in grading LGGs from HGGs. The combination of Tofts_Ve histogram metrics was the one with the highest accuracy (81.67%) and area under ROC curve (AUC = 0.840). On the other hand, Patlak_Ktrans 95th (AUC = 0.9265) and Extended Tofts_Ve 95th (AUC = 0.9154) performed better than their corresponding means (Patlak_Ktrans mean: AUC = 0.9118 and Extended Tofts_Ve mean: AUC = 0.9044) in predicting patients' overall survival (OS) at 18-month follow-up.
CONCLUSION: DCE-MRI-derived histogram features from the entire tumor were promising metrics for glioma grading and OS prediction. Combining single modal histogram features improved glioma grading. TRIAL REGISTRATION: NCT02622620.
© 2019 Yan et al.

Entities:  

Keywords:  glioma grading; histogram features; multi-modal MRI; receiver operating curve; survival analysis

Year:  2019        PMID: 31819632      PMCID: PMC6885544          DOI: 10.2147/CMAR.S197839

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


Introduction

Glioma is the most common primary central nervous system (CNS) tumor, with high incidence and low overall survival (OS) rate. According to the World Health Organization (WHO) criteria in 2007,1 gliomas are classified into low-grade gliomas (LGGs, including WHO grades I and II gliomas) and high-grade gliomas (HGGs, including WHO grades III and IV gliomas). The optimal treatment strategies highly depend on the glioma features (including tumor grading and pathological composition), as does patient survival. Although the histopathological characteristics of glioma are used as the gold standard biomarker for grading tumor and predicting patient survival, its application has been limited by the fact of not-timely post-operative sampling and inability to reflect the tumor heterogeneity. Thus, preoperative glioma grading and survival analysis based on the entire tumor features are urgently required. Non-invasive MRI techniques are particularly valuable in glioma grading and survival prediction, but consensus has not been reached regarding the optimal technique. By using conventional magnetic resonance imaging (MRI) techniques, glioma grading accuracies ranged from 55% to 83% based on tumor enhancement and necrosis.2 However, the remarkable difference between LGGs and HGGs exists in the tumor microenvironments that can not be fully revealed with conventional MRI techniques. Fortunately, current advanced MR sequences, especially arterial spin labeling (ASL), intravoxel incoherent motion-diffusion weighted imaging (IVIM-DWI), and dynamic contrast-enhanced MRI (DCE-MRI), have been hypothesized to reflect the tumor perfusion, diffusion, and blood–brain barrier (BBB) permeability;3–6 thus these techniques are increasingly employed for tumor grading7–10 and predicting patients’ survival.3,11 Despite the promising outcome of these advanced MRI techniques, several issues should be addressed before their clinical applications. Previous studies were conducted mainly based on single modal advanced MRI, which partly reveals the tumor microenvironment features. Additionally, it is almost impossible to determine which parameter or sequence is the most impactful on tumor grading and survival prediction since the study populations for even the same research purpose were different concerning the epidemiological background. Lastly, in most studies, only the mean, maximum, minimum, or median value of a specific parameter within the 2-dimensional tumor region of interest (ROI) was utilized, leaving most of the informative histogram indicators within the entire tumor underestimated. To make the best use of advanced MRIs, it is important to conduct a comprehensive investigation in a relatively large representative glioma patient population receiving DWI-, DCE-, and ASL-MRI scans to determine the most impactful functional parameters from the 3-dimensional volume of interest (VOI) using the informative histogram indicators analyses. Thus, we performed the current study on glioma patients to address these issues and further investigated the efficacies of parameter combinations in glioma grading and survival prediction.

Materials And Methods

Patient Population

The data of the current project were derived from a diagnostic trial that has been registered to ClinicalTrials.gov (NCT 02622620, ) with the trial protocol12 and part of the data were published.13,14 This study was conducted in accordance with the Declaration of Helsinki of 1975 in its most recent version. This study was approved by Ethics Committee of Tangdu Hospital of the Fourth Military Medical University, and informed consent was obtained prior to the enrollment. From January 2014 to March 2016, 120 patients with pathologically confirmed gliomas were included in the current study. The patients were followed up till August 31, 2016. Excluding the patients without follow-up information, 90 patients who were alive or died of glioma-related disease were fed to survival analysis at 12-, 15-, and 18-month intervals from the date of surgery. The inclusion and exclusion criteria were shown in . Differences of permeability (A, B), perfusion (C), and diffusion (D) parameters between LGGs and HGGs. All parameters, except Vp post-processed with extended Tofts, are significantly different between the two groups. * = P < 0.05, ** = P < 0.01, *** = P < 0.001, + = Mean, line in box = median, boundaries of boxes = interquartile range, whiskers = Turkey, and · = outlier.

Image Data Acquisition

The MRI protocol was implemented on a 3.0-T MRI scanner (MR750, GE Healthcare, Milwaukee, Wisconsin, USA) with 8 channel head coil. Conventional MRI scans included axial T1-weighted spin-echo images (T1WI), T2-weighted fast spin-echo images (T2WI), fluid-attenuated inversion recovery (FLAIR), and T1-weighted contrast-enhanced images (T1CE). In addition to conventional MRI scans, advanced MR scans including three-dimensional ASL (3D-ASL), multiple b value DWI (multi-b DWI), and DCE-MRI were obtained (), for each patient. All MR scans were acquired in axial planes (). The 3D-ASL was a pseudo-continuous arterial spin-labeling sequence using 3D segmented spiral readouts with the post-label delay time of 1.525 s. The multi-b DWI, a diffusion-weighted echo-planar sequence, was implemented with a single shot spin-echo using 13 different b-values (0, 30, 50, 100, 200, 300, 500, 800, 1000, 1500, 2000, 3000, 3500 s/mm2) in 3 orthogonal directions as described in our previous study.15 The DCE-MRI was performed with a 50-phase dynamic gradient-echo T1 scanning and each phase was 4 s. The bolus of gadodiamide contrast material (0.5 mmol, 0.2mL/kg, Omniscan, GE Healthcare, Ireland, UK) was injected using high-pressure injector at the rate of 2mL/s at the end of the 5th phase, followed by normal saline injection.

Image Processing And Data Analysis

The cerebral blood flow (CBF) map was derived from 3D-ASL images using the GE ADW4.6 workstation (GE Healthcare, Milwaukee, Wisconsin, USA), while the raw images of multi-b DWI and DCE-MRI were transferred and post-processed with corresponding modules integrated to the NordicICE (Version 4.0, Nordic-NeuroLab, Bergen, Norway) analysis platform. The parametric maps derived from multi-b DWI were based on the biexponential IVIM analytic model.16 The DCE images were processed using Patlak,17 Tofts,18 extended Tofts,19 and Incremental models (the optimal model using a statistical test in NordicICE). The semiquantitative parameters were calculated based on fixed T1 values (1000 ms).20 A standard population-based arterial input function (AIF) was automatically defined. In addition, the initial area under gadolinium concentration–time curve (IAUGC) was acquired for the first-pass data (90 s) and model-free parameters were retrieved. All parameters derived from multi-modal MRI are listed in Table 1.
Table 1

The Models And Corresponding Parameters Derived From Advanced MRI

ModalityModelParameters
3D-ASLCBF
Multi-b DWIIVIMD, D*fslow, f fast
DCE-MRIPatlakKtrans, Vp
ToftsKtrans, Ve, Vp
Extended ToftsKtrans, Kep, Ve, Vp
IncrementalKtrans, Ve, Vp
Model-freeIAUGC90, BF, BAT, TTP, Peak

Abbreviations: CBF, cerebral blood flow; ADC, apparent diffusion coefficient; D, slow ADC; D*fast ADC; fslow, slow fractional ADC; ffast, fast fractional ADC; EES, extravascular-extracellular space; Ktrans, transfer coefficient between the plasma and EES; Kep, transfer coefficient between the EES and plasma; Ve, volume of EES; Vp, volume of plasma; IAUGC90, the initial area under gadolinium concentration–time curve for the first-pass data (90 s); BF, blood flow; BAT, bolus arrived time; TTP, time to peak.

The Models And Corresponding Parameters Derived From Advanced MRI Abbreviations: CBF, cerebral blood flow; ADC, apparent diffusion coefficient; D, slow ADC; D*fast ADC; fslow, slow fractional ADC; ffast, fast fractional ADC; EES, extravascular-extracellular space; Ktrans, transfer coefficient between the plasma and EES; Kep, transfer coefficient between the EES and plasma; Ve, volume of EES; Vp, volume of plasma; IAUGC90, the initial area under gadolinium concentration–time curve for the first-pass data (90 s); BF, blood flow; BAT, bolus arrived time; TTP, time to peak.

Tumor Segmentation Or Delineation

The VOI segmentation was manually drawn using NordicICE by two neuroradiologists (LF.Y, 12 years of experience and YC.H, 12 years of experience) who were blind to histopathological results. Multi-modal parametric maps were resampled using Nordic ICE. The VOIs covered the enhanced tumor part after thresholding on T1CE images and were then overlaid on T2 FLAIR where the hyperintense parts were delineated.21,22 The regions of edema, necrosis, or non-tumor macrovessels were avoided. The pixel-by-pixel values within VOIs were extracted from each parametric map.

Histogram Analysis

The histogram metrics23 including mean, median, max, min, skewness, kurtosis, energy, and entropy as well as the cumulative histogram indicators expressed as the nth percentiles were calculated. The 75th, 90th, and 95th percentiles were obtained from permeability and perfusion parameters, whereas the 5th, 10th, and 25th percentiles were derived from diffusion ones.

Statistical Analysis

An unpaired Student’s t-test or Mann–Whitney U-test was used to compare each histogram metric value between LGGs and HGGs. The receiver operating characteristic (ROC) curve analyses with area under the curve (AUC) were used to evaluate the diagnostic efficacy. Multivariable stepwise logistic regression for parameter combination was performed with Statistical Package for the Social Sciences (SPSS, Version 20.0, SPSS Inc., Chicago, IL, USA). In addition, leave-one-out cross-validation (LOOCV) was further used to validate the accuracy of the combined parameters in glioma grading by using WEKA software (Version 3.8.0, the University of WAIKATO). The log-rank test using the Kaplan–Meier curve was applied to predict overall survival (OS) at 12, 15, or 18 months after surgery.

Results

Patients’ Baseline Characteristics

The clinical characteristics of patients are listed in Table 2. Among the 120 glioma patients, 28 patients were diagnosed with LGGs and 92 patients were diagnosed with HGGs. HGG patients were older than LGG patients (P = 0.0002). There is no significant difference in gender (P = 0.2980) or tumor location (P = 0.0600) between the two groups.
Table 2

Clinical Characteristics Of Patients

VariableLGGsHGGsP-Value
Grade I Grade IIGrade III Grade IV
No. of patientsn = 28n = 92NA
Genderb
 Male13 (46.4%)53 (57.6%)0.2980
 Female15 (53.6%)39 (42.3%)
Agea
 Mean35.9 ± 16.249.3 ± 15.00.0002*
Locationc
 Supratentorial25 (89.3%)91 (98.9%)0.0600
 Subtentorial3 (10.7%)1 (1.1%)
Extent of resection (EOR)
 Gross total resection (GTR)26 (92.9%)65 (70.7%)NA
 Subtotal resection (STR)2 (7.1%)26 (28.3%)NA
 Biopsy01 (1%)NA
Histopathology
 Pilocytic astrocytoma2 (7.1%)NA
 Ganglioglioma1 (3.6%)NA
 Pleomorphic xanthoastrocytoma1 (3.6%)NA
 Diffuse astrocytoma11 (39.3%)NA
 Oligodendroglioma2 (7.1%)NA
 Oligoastrocytoma11 (39.3%)NA
 Anaplastic astrocytoma7 (7.6%)NA
 Anaplastic oligodendroglioma5 (5.4%)NA
 Anaplastic oligoastrocytoma17 (18.5%)NA
 Glioblastoma62 (67.4%)NA
 Gliosarcoma1 (1.1%)NA
Adjuvant therapy
 Radiation9 (32.1%)15 (16.3%)NA
 Chemotherapy5 (17.9%)11 (12.0%)NA
 Chemoradiotherapy8 (28.6%)56 (60.9%)NA
 Unknown6 (21.4%)10 (10.9%)NA

Notes: Except where indicated, data are numbers of patients, and numbers in parentheses are percentage. aData are mean ± standard deviation. Difference between LGGs and HGGs was evaluated with unpaired Student t-testa, the Pearson Chi-Square,b and Continuity Correctionc. *Indicating significant difference between groups (P < 0 0.05).

Clinical Characteristics Of Patients Notes: Except where indicated, data are numbers of patients, and numbers in parentheses are percentage. aData are mean ± standard deviation. Difference between LGGs and HGGs was evaluated with unpaired Student t-testa, the Pearson Chi-Square,b and Continuity Correctionc. *Indicating significant difference between groups (P < 0 0.05).

Differences In Multi-Modal Parameters Between LGG And HGG Patients

Among the permeability parameters from DCE-MRI, despite the varied models used, the values of Ktrans (P < 0.0001, = 0.0004, 0.0002, or 0.0003 for Patlak, Tofts, Extended Tofts, or Incremental model, respectively), Ve (P < 0.0001, 0.0001, or 0.0001 for Tofts, Extended Tofts, or Incremental model, respectively), and Vp (P = 0.0003 for Patlak model) were significantly increased, while those of Kep (P = 0.0009, 0.0028, or 0.0016 for Tofts, Extended Tofts, or Incremental model, respectively) were significantly decreased in HGG patients. Among the perfusion parameters derived from 3D-ASL, IVIM-DWI, or DCE images, the values of IAUGC90 (P < 0.0001), BF (P = 0.0026), Peak (P = 0.0019), TTP (P = 0.0346), and ADCfast (P = 0.0333) were significantly decreased, nevertheless those of CBF (P = 0.0136) and ffast (P = 0.0029) were significantly increased in HGG patients. The diffusion parameters obtained from IVIM-DWI images, i.e., ADCslow and fslow (P < 0.0001, = 0.0019), were significantly decreased in HGG patients (Figure 1). Corresponding ROC curves were established and the AUC, diagnostic specificity, and sensitivity of ROC based on the mean of each parameter are summarized in . The mean of DCE_IAUGC90, Ve from varied models (i.e., Tofts_Ve, Extended Tofts_Ve, Incremental_Ve), Ktrans from Patlak (Patlak_Ktrans), and ADCslow from IVIM model (IVIM_ADCslow) performed better (P < 0.0001).
Figure 1

Differences of permeability (A, B), perfusion (C), and diffusion (D) parameters between LGGs and HGGs. All parameters, except Vp post-processed with extended Tofts, are significantly different between the two groups. * = P < 0.05, ** = P < 0.01, *** = P < 0.001, + = Mean, line in box = median, boundaries of boxes = interquartile range, whiskers = Turkey, and · = outlier.

Diagnostic Performance Of Histogram Metrics For Glioma Grading

To improve the diagnostic efficacies, we further tested histogram metrics’ performance in glioma grading. The AUCs and P values of the six parameters (Patlak_Ktrans, Tofts_Ve, Extended Tofts_Ve, Incremental_Ve, DCE_IAUGC90, and IVIM_ADCslow) and their corresponding histogram metrics are listed in . Only Extended Tofts_Vemedian and Incremental_Ve75th were with higher accuracies than their means (Extended Tofts_Ve: mean = 68.33%, median = 71.67%; Incremental_Ve: mean = 68.33%, 75th = 72.50%) (Table 3). However, Patlak_Ktransmean (75.83%) was demonstrated to have the highest accuracy in glioma grading. The representative parametric maps and histograms are also shown in Figure 2.
Table 3

Histogram Measure Of Multi-Modal Parameters In Differentiating LGGs From HGGs

AUC*(95% CI)Cutoff ValueSensitivity(%)*(95% CI)Specificity(%)*(95% CI)Accuracy(%)
Patlak_Ktrans
Mean0.7896 (0.6833–0.8959)0.008875.00(64.89–83.45)78.57(59.05–91.70)75.83
90th percentile0.7972*(0.6909–0.9034)0.022571.74(61.39–80.64)78.57(59.05–91.70)73.33
Extended Tofts_Ve
Mean0.8005 (0.7001–0.9008)11.8563.04(52.34–72.88)85.71(67.33–95.97)68.33
Median0.8007*(0.7150–0.8863)368.48(57.96–77.77)82.14(63.11–93.94)71.67
Incremental_Ve
Mean0.7892 (0.6893–0.8891)8.84763.04(52.34–72.88)85.71(67.33–95.97)68.33
75th percentile0.7962*(0.7084–0.8840)5.370.65(60.24–79.69)78.57(59.05–91.70)72.50
Perfusion_IAUGC90
Mean0.8133 (0.7298–0.8967)2.2567.39(56.82–76.80)85.71(67.33–95.97)71.67
Max0.8296*(0.7587–0.9004)96.2063.00(52.34%-72.88)100.00(87.66%-100.0)71.67

Notes: Bold underlined data indicate histogram metrics which have higher accuracies than the relative means. Bold asterisk data indicate the histogram metric which has a higher AUC compared with the relative mean (P < 0.05).

Abbreviation: AUC, area under curve. 

Figure 2

Multi-modal parameter maps and histograms from a representative LGG and HGG patients, respectively. (A) Images of a 45-year-old patient with grade II glioma. The VOI was drawn on FLAIR. (B) Images of a 63-year-old patient with grade IV glioma. The VOI is obtained from FLAIR or T1CE. HGG (B) is associated with increased Tofts_Ve, Extend Tofts_Ve, Incremental_Ve, Patlak_Ktrans and decreased DCE_IAUGC90, IVIM_ADCslow values within the VOI. Histograms and corresponding cumulative curves for Extended Tofts_Ve (C) and Incremental_Ve (D) in patients A and B, showing a left-shifted cumulative curve (smaller mean value) in LGG for both parameters.

Histogram Measure Of Multi-Modal Parameters In Differentiating LGGs From HGGs Notes: Bold underlined data indicate histogram metrics which have higher accuracies than the relative means. Bold asterisk data indicate the histogram metric which has a higher AUC compared with the relative mean (P < 0.05). Abbreviation: AUC, area under curve. Multi-modal parameter maps and histograms from a representative LGG and HGG patients, respectively. (A) Images of a 45-year-old patient with grade II glioma. The VOI was drawn on FLAIR. (B) Images of a 63-year-old patient with grade IV glioma. The VOI is obtained from FLAIR or T1CE. HGG (B) is associated with increased Tofts_Ve, Extend Tofts_Ve, Incremental_Ve, Patlak_Ktrans and decreased DCE_IAUGC90, IVIM_ADCslow values within the VOI. Histograms and corresponding cumulative curves for Extended Tofts_Ve (C) and Incremental_Ve (D) in patients A and B, showing a left-shifted cumulative curve (smaller mean value) in LGG for both parameters.

Parameter Combination For Glioma Grading

For the six parameters, multivariable logistic regression was performed to evaluate the efficacies of combined histogram metrics in glioma grading. Only the combination of Ve metrics (AUC = 0.8688, 0.8401, 0.8575, P < 0.0001, 0.0001, or 0.0001 for Tofts, Extended Tofts, or Incremental model, respectively) was associated with the increased diagnostic efficacies compared with their single histogram metrics. Moreover, combined mean metrics of the six parameters (AUC = 0.8611, P < 0.0001) performed better than the single mean as well (Figure 3). Thus, the combination of variables from either histogram metrics or multi-modal parameters could improve the efficacies of glioma grading.
Figure 3

Diagnostic performance of multivariable logistic regression selected individual metrics or their combination in differentiating LGGs from HGGs. The ROC curves of (A) max, kurtosis, energy of Tofts_Ve as well as their combination; (B) max, 75th, 95th and kurtosis of Incremental_Ve as well as their combination; (C) max, 95th and entropy of Extended Tofts_Ve as well as their combination; (D) DCE_IAUGC90mean, IVIM_ADCslowmean, DCE_TTPmean as well as their combination.

Diagnostic performance of multivariable logistic regression selected individual metrics or their combination in differentiating LGGs from HGGs. The ROC curves of (A) max, kurtosis, energy of Tofts_Ve as well as their combination; (B) max, 75th, 95th and kurtosis of Incremental_Ve as well as their combination; (C) max, 95th and entropy of Extended Tofts_Ve as well as their combination; (D) DCE_IAUGC90mean, IVIM_ADCslowmean, DCE_TTPmean as well as their combination. We further validated the accuracies of the combined metrics using LOOCV strategy. Only the combination of Tofts_Ve histogram metrics (max, kurtosis, and energy were combined) showed increased accuracy (81.67%, AUC = 0.840) (Table 4).
Table 4

Leave-One Out Cross-Validation For Combined Diagnostic Efficacies With Multivariate Logistic Regression

AUCSensitivity (%)Specificity (%)Accuracy (%)
Tofts_Ve
 Max0.34379.2041.5079.16
 Kurtosis0.54376.7030.8076.67
 Energy0.67577.5031.0077.50
 Max+kurtosis+energy0.840*81.7057.2081.67
Incremental_Ve
 Max0.40078.3043.7078.33
 75th percentile0.73776.7023.3076.67
 95th percentile0.70576.7023.3076.67
 Kurtosis0.51879.2036.5079.17
 Max+75th+95th+kurtosis0.814*78.3053.7078.33
Extended Tofts_Ve
 Max0.24377.5036.0077.50
 90th percentile0.66576.7023.3076.67
 Entropy0.74079.2036.5079.17
 Max+90th+entropy0.804*76.7043.2076.67
Multimodality
 IAUGCmean0.74378.3043.7078.33
 TTPmean0.56775.8025.6075.83
 sADCmean0.72275.8033.0075.83
 IAUGC90mean+TTPmean0.815*75.8043.0075.83
 IAUGC90mean+TTPmean+sADCmean0.835*78.3053.7078.33

Notes: Bold underlined data indicate the accuracy of combined histogram metrics is higher than that of single histogram metrics. Bold asterik data indicate the combined histogram metrics have higher AUCs than single metrics (P < 0.05).

Abbreviation: AUC, area under curve.

Leave-One Out Cross-Validation For Combined Diagnostic Efficacies With Multivariate Logistic Regression Notes: Bold underlined data indicate the accuracy of combined histogram metrics is higher than that of single histogram metrics. Bold asterik data indicate the combined histogram metrics have higher AUCs than single metrics (P < 0.05). Abbreviation: AUC, area under curve.

Survival Prediction

ROC analyses were first used to evaluate efficacies of the mean values for predicting OS at 12, 15, and 18 months after surgery. Multi-modal parameters achieved mild to moderate prognostic powers at varied time points. Among the means, Patlak_Ktransmean (AUC = 0.9118, P = 0.0003) and Extended Tofts_Vemean (AUC = 0.9044, P = 0.0004) were the two optimal predictors which performed better at 18 months follow-up than at 12 or 15 months (). We further evaluated the roles of histogram metrics in predicting OS at 12, 15, and 18 months after surgery. The 95th percentiles of Patlak_Ktrans (AUC = 0.9265, P = 0.0002) and Extended Tofts_Ve (AUC = 0.9154, P = 0.0003) performed best at 18-month follow-up (), and corresponding ROC curves of the means and 95th percentiles are shown in Figure 4.
Figure 4

ROC analysis of histogram parameters in predicting patients’ survival. The ROC curves of (A) Patlak_Ktransmean, (B) Extended Tofts_Vemean, (C) Patlak_Ktrans95th, or (D) Extended Tofts_Ve95th for predicting patient survival at 12, 15, or 18 months after diagnosis.

ROC analysis of histogram parameters in predicting patients’ survival. The ROC curves of (A) Patlak_Ktransmean, (B) Extended Tofts_Vemean, (C) Patlak_Ktrans95th, or (D) Extended Tofts_Ve95th for predicting patient survival at 12, 15, or 18 months after diagnosis. Log-rank test using Kaplan–Meier curve was performed to predict OS at varied follow-up time points. Using the medians of each metric, the patients were stratified into two groups. As for Patlak_Ktrans (Figure 5), the 95th percentile could predict 12-, 15-, or 18-month OS (P = 0.0109, 0.0373, 0.0157), but the mean metric (P = 0.0636, 0.0952, or 0.0755 for 12-, 15-, or 18-month OS) were not significantly effective. As for Extended Tofts_Ve (Figure 6), the 95th percentile (P = 0.0031, 0.0143, or 0.0063, for 12-, 15- or 18-month OS, respectively) also performed better than the mean (P = 0.0216, 0.0408, or 0.0423, for 12-, 15-, or 18-month OS, respectively). In brief, the histogram metrics like 95th percentile did improve the performance of Patlak_Ktrans and Extended Tofts_Ve for OS prediction.
Figure 5

The Kaplan–Meier survival analysis of Patlak_Ktransmean (A, B, C) or Patlak_Ktrans95th (D, E, F). Kaplan–Meier curves of Patlak_Ktransmean for patient survival at 12 (A), 15 (B), or 18 (C) months after surgery. Kaplan–Meier curves of Patlak_Ktrans95th for patient survival at 12 (D), 15 (E), or 18 (F) months after surgery. Patlak_Ktrans95th performed better than Patlak_Ktrans mean based on the different P values (*P < 0.05).

Figure 6

The Kaplan–Meier survival analysis of Extended Tofts_Vemean (A, B, C) or Extended Tofts_Ve95th (D, E, F). Kaplan–Meier curves of Extended Tofts_Vemean for patient survival at 12 (A), 15 (B), or 18 (C) months after surgery. Kaplan–Meier curves of Extended Tofts_Ve95th for patient survival at 12 (D), 15 (E), or 18 (F) months after surgery. Extended Tofts_Ve95th performed better than Extended Tofts_Vemean based on the different P values (*P < 0.05, **P < 0.01).

The Kaplan–Meier survival analysis of Patlak_Ktransmean (A, B, C) or Patlak_Ktrans95th (D, E, F). Kaplan–Meier curves of Patlak_Ktransmean for patient survival at 12 (A), 15 (B), or 18 (C) months after surgery. Kaplan–Meier curves of Patlak_Ktrans95th for patient survival at 12 (D), 15 (E), or 18 (F) months after surgery. Patlak_Ktrans95th performed better than Patlak_Ktrans mean based on the different P values (*P < 0.05). The Kaplan–Meier survival analysis of Extended Tofts_Vemean (A, B, C) or Extended Tofts_Ve95th (D, E, F). Kaplan–Meier curves of Extended Tofts_Vemean for patient survival at 12 (A), 15 (B), or 18 (C) months after surgery. Kaplan–Meier curves of Extended Tofts_Ve95th for patient survival at 12 (D), 15 (E), or 18 (F) months after surgery. Extended Tofts_Ve95th performed better than Extended Tofts_Vemean based on the different P values (*P < 0.05, **P < 0.01).

Discussion

In this study, we revealed that DCE-MRI performed better than 3D-ASL or IVIM-DWI in both glioma grading and survival prediction. The mean or histogram metrics of IAUGC90, Ve, and Ktrans were associated with the higher grading efficacies. The mean or the 95th percentile values of Extended Tofts_Ve and Patlak_Ktrans were with the higher efficacies to predict OS. The combination of multiple histogram metrics of a single MRI parameter or means from multi-modal parameters was associated with increased glioma grading efficacy. The mean or histogram metrics of Ktrans and Ve (independent from the pharmacokinetics algorithm) are associated with higher efficacies in glioma grading. However, only Ve histogram metrics were survived from multivariable stepwise regression for glioma grading. DCE-MRI derived parameters, especially Ktrans and Ve, were important imaging biomarkers for glioma grading,3,7,24–27 with similar efficacies.24,26 But a VOI-based histogram analysis revealed that histogram metrics of Ktrans but not that of Ve survived from multivariable stepwise regression.28 One possible explanation is that previous studies suffered from small patient population number (28,28 compared with 120 in the current study). However, further validation of Ktrans and Ve for glioma grading is needed before a consolidated conclusion is drawn. Our study also demonstrated that Ve and Ktrans are promising prognostic factors for glioma patients’ OS. Some studies reported that high Ktrans or Ve was associated with significantly poor prognosis for glioma patients in both univariate and multivariate survival analyses.11 On the other hand, some studies suggested that there was no close relationship between permeability parameters from DCE and glioma survival, making Ktrans not a consistent survival predictor.29,30 Our study was different from previous ones concerning the subject number (90 of ours vs 69, 49 in previous ones), pharmacokinetic models used (4 models of ours vs only one in previous ones) and the tumor coverage methods (our VOI-based histogram analysis vs ROI-based analysis in other studies). Although more patients, varied models, and advanced VOI-based analysis were used in our study, the prognosis of glioma patients was still affected by multiple factors, such as age, histological type, molecular phenotype, extent of resection (EOR), post-operative neurological function, and adjuvant therapy.31,32 Using volumetric computations of the LGGs, EOR was demonstrated as an independent prognostic factor, even better than genetic markers.33 Another meta-analysis suggested that gross total resection (GTR) is associated with a better OS than subtotal resection (STR) and biopsy in HGGs.34 Postoperative neurological status is dynamically altered in varied therapeutic protocols including EOR and adjuvant therapy which may drastically influence OS.35–37 In our cohort, more than 92% LGGs and 70.7% HGGs were with GTR. Besides, due to adjuvant therapy and neurological status evaluation after surgery regulated by multicenter clinical experts, post-operative records would not be obtained in our institution. Therefore, our OS prediction was biased because only preoperative MRI was used, and it needs to be analyzed with multivariate cox regression regarding the therapies, histological grading, and clinical and molecular information in future studies. The combination of multiple histogram metrics from a single parameter or means from multi-modal parameters was associated with the increased glioma grading efficacy. The combination of histogram metrics of Ve derived from Tofts model performed the best. This is quite consistent with previous studies showing that the multi-modal combinations are superior to single modal parameter38 for glioma grading.39–43 In addition, the efficacy of histogram metrics is superior to that of the mean when predicting patient survival. This histogram method is promising for clinical use after we reach the balance between labor cost and efficacy improvement. Perfusion MR imaging technique such as dynamic susceptibility contrast (DSC) is widely used in the clinical work-up of brain tumors because of their ability to help quantify tumor microvessel proliferation. However, DCE was implemented in our study because DCE signal intensity time curve reflects a combination of tissue perfusion, microvessel permeability, and extravascular-extracellular space. A comprehensive meta-analysis has shown that both DCE and DSC are reliable techniques in differentiating glioma grades.44 A new multi-center standardized assessment demonstrated that DCE-derived Ktrans, Ve, and initial area under the concentration curve (iAUC) had higher accuracies than the metric from DSC for differentiating grade II from III or IV gliomas.45 Therefore, DCE was applicable for evaluating both perfusion and permeability of microvessel in clinical work-up of brain tumors. There are some limitations for the current study. First, the prospective clinical trial from 2014 to 2016 was designed according to WHO 2007 grading criteria which has now been replaced by WHO 2016 grading criteria. Second, the number of patients with LGGs is relatively small compared with the number of HGGs patients and may have biased our final conclusion. Third, we did not utilize multivariable cox regression to predict OS, ignoring clinical characteristics effect.

Conclusions

In summary, we offered evidence that DCE-MRI performed better than 3D-ASL or IVIM-DWI in both glioma grading and survival prediction. Ktrans and Ve were associated with the higher glioma grading efficacies using either mean or histogram metrics. Combination of Ve histogram metrics was the one with the highest glioma grading accuracy. The mean or the 95th values of Ve and Ktrans were with the higher efficacies for survival prediction.
  45 in total

1.  Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas.

Authors:  Na Zhang; Lijuan Zhang; Bensheng Qiu; Li Meng; Xiaoyi Wang; Bob L Hou
Journal:  J Magn Reson Imaging       Date:  2012-05-11       Impact factor: 4.813

Review 2.  Comparative assessment of the efficacy of gross total versus subtotal total resection in patients with glioma: A meta-analysis.

Authors:  Shuang Tang; Jin Liao; Yong Long
Journal:  Int J Surg       Date:  2019-02-08       Impact factor: 6.071

3.  The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Zhong Zheng Jia; Hong Mei Gu; Xue Jun Zhou; Jin Long Shi; Min Da Li; Guo Feng Zhou; Xian Hua Wu
Journal:  Eur J Radiol       Date:  2015-06-05       Impact factor: 3.528

4.  Radiomics strategy for glioma grading using texture features from multiparametric MRI.

Authors:  Qiang Tian; Lin-Feng Yan; Xi Zhang; Xin Zhang; Yu-Chuan Hu; Yu Han; Zhi-Cheng Liu; Hai-Yan Nan; Qian Sun; Ying-Zhi Sun; Yang Yang; Ying Yu; Jin Zhang; Bo Hu; Gang Xiao; Ping Chen; Shuai Tian; Jie Xu; Wen Wang; Guang-Bin Cui
Journal:  J Magn Reson Imaging       Date:  2018-03-23       Impact factor: 4.813

5.  Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas.

Authors:  Xiao-chun Wang; Hui Zhang; Yan Tan; Jiang-bo Qin; Xiao-feng Wu; Le Wang; Lei Zhang
Journal:  J Magn Reson Imaging       Date:  2014-06       Impact factor: 4.813

6.  Intravoxel incoherent motion diffusion-weighted MR imaging of gliomas: feasibility of the method and initial results.

Authors:  Sotirios Bisdas; Tong San Koh; Constantin Roder; Christian Braun; Jens Schittenhelm; Ulrike Ernemann; Uwe Klose
Journal:  Neuroradiology       Date:  2013-07-14       Impact factor: 2.804

7.  Parameters assessing neurological status in malignant glioma patients: prognostic value for survival and relapse-free time.

Authors:  R Martinez; C Volter; R Behr
Journal:  Br J Neurosurg       Date:  2008-08       Impact factor: 1.596

8.  Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.

Authors:  Hyun Seok Choi; Ah Hyun Kim; Sung Soo Ahn; Na-young Shin; Jinna Kim; Seung-Koo Lee
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

9.  Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.

Authors:  Yu Han; Lin-Feng Yan; Xi-Bin Wang; Ying-Zhi Sun; Xin Zhang; Zhi-Cheng Liu; Hai-Yan Nan; Yu-Chuan Hu; Yang Yang; Jin Zhang; Ying Yu; Qian Sun; Qiang Tian; Bo Hu; Gang Xiao; Wen Wang; Guang-Bin Cui
Journal:  BMC Cancer       Date:  2018-02-21       Impact factor: 4.430

10.  Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced MR in Tumor Parenchyma and Peritumoral Area for Distinction of Brain Tumors.

Authors:  Jing Zhao; Zhi-yun Yang; Bo-ning Luo; Jian-yong Yang; Jian-ping Chu
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

View more
  2 in total

1.  The diagnostic value of intravoxel incoherent motion imaging in differentiating high-grade from low-grade gliomas: a systematic review and meta-analysis.

Authors:  Hechuan Luo; Ling He; Weiqin Cheng; Sijie Gao
Journal:  Br J Radiol       Date:  2021-05-01       Impact factor: 3.039

2.  Hybrid PET-MRI Imaging in Paediatric and TYA Brain Tumours: Clinical Applications and Challenges.

Authors:  Ananth Shankar; Jamshed Bomanji; Harpreet Hyare
Journal:  J Pers Med       Date:  2020-11-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.